ResearcherJichi Medical UniversityActive in the last 2 years
Fumiaki Watanabe
Matched on ORCID iD 0000-0002-8154-9905; OpenAlex author ID A5017061440. Sources: OpenAlex.
Their work
- Papers
- 7
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 4
2019: 2 papers · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper
Papers 7
- DNA Hypomethylation in Pancreatic Cancer Tissues Before Treatment, Defined by KRAS -mutated Circulating Tumor DNA, is Associated With Poor Prognosis. Co-author DOI 10.1097/mpa.0000000000002650↗
- Circulating tumor DNA in molecular assessment feasibly predicts early progression of pancreatic cancer that cannot be identified via initial imaging. Co-author DOI 10.1038/s41598-023-31051-7↗
- Liquid biopsy leads to a paradigm shift in the treatment of pancreatic cancer. Co-author DOI 10.3748/wjg.v28.i46.6478↗
- Genome‑wide DNA hypomethylation drives a more invasive pancreatic cancer phenotype and has predictive occult distant metastasis and prognosis potential. Co-author DOI 10.3892/ijo.2022.5351↗
- Optimal value of CA19-9 determined by KRAS-mutated circulating tumor DNA contributes to the prediction of prognosis in pancreatic cancer patients. Co-author DOI 10.1038/s41598-021-00060-9↗
- A lack of postoperative complications after pancreatectomy contributes to the long-term survival of patients with pancreatic cancer. Co-author DOI 10.1016/j.pan.2019.06.012↗
- Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer. Co-author DOI 10.1371/journal.pone.0227366↗
Closest collaborators
The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Toshiki Rikiyama · 7 shared papers, 2019–2026 · strength 1.12
- Paper DNA Hypomethylation in Pancreatic Cancer Tissues Before Treatment, Defined by KRAS -mutated Circulating Tumor DNA, is A… DOI 10.1097/mpa.0000000000002650↗
- Paper Liquid biopsy leads to a paradigm shift in the treatment of pancreatic cancer. DOI 10.3748/wjg.v28.i46.6478↗
- Paper Circulating tumor DNA in molecular assessment feasibly predicts early progression of pancreatic cancer that cannot be i… DOI 10.1038/s41598-023-31051-7↗
- Yuhei Endo · 6 shared papers, 2019–2026 · strength 0.90
- Paper DNA Hypomethylation in Pancreatic Cancer Tissues Before Treatment, Defined by KRAS -mutated Circulating Tumor DNA, is A… DOI 10.1097/mpa.0000000000002650↗
- Paper Circulating tumor DNA in molecular assessment feasibly predicts early progression of pancreatic cancer that cannot be i… DOI 10.1038/s41598-023-31051-7↗
- Paper Genome‑wide DNA hypomethylation drives a more invasive pancreatic cancer phenotype and has predictive occult distant me… DOI 10.3892/ijo.2022.5351↗
- Koetsu Inoue · 1 shared paper, 2026 · strength 0.28
- Naoya Kasahara · 1 shared paper, 2019 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.